E-health. Patterns of use and perceived benefits and barriers among people living with HIV and their physicians. Part 2: Health apps and smart devices [0.03%]
艾滋病毒患者及其医生使用电子健康的情况、感受的益处和障碍模式（第二部分：健康APP和智能设备）
C Jacomet,R Ologeanu-Taddei,J Prouteau et al.
C Jacomet et al.
Objectives: To evaluate patterns of use and perceived benefits and barriers to health/wellness applications (apps) and smart devices among people living with HIV (PLHIV) and their physicians. ...
Multicenter Study
Medecine et maladies infectieuses. 2020 Oct;50(7):582-589. DOI:10.1016/j.medmal.2020.04.005 2020
E-health. Patterns of use and perceived benefits and barriers among people living with HIV and their physicians. Part 1: Information retrieval on the Internet and social networks [0.03%]
电子健康。HIV患者及其医生使用该系统的情况、所感知到的好处及障碍。第一部分：互联网和社交网络上的信息检索
C Jacomet,P Bastiani,J Prouteau et al.
C Jacomet et al.
Objectives: To identify patterns of use, perceived benefits, and barriers among people living with HIV (PLHIV) of online searches for health information and via social media. ...
Observational Study
Medecine et maladies infectieuses. 2020 Oct;50(7):575-581. DOI:10.1016/j.medmal.2020.04.004 2020
Six-week antibiotic therapy after one-stage replacement arthroplasty for hip and knee periprosthetic joint infection [0.03%]
一期置换术后髋关节和膝关节假体周围关节感染的六周抗生素疗法
G Chieffo,S Corsia,G Rougereau et al.
G Chieffo et al.
Objectives: One-stage replacement arthroplasty for treatment of periprosthetic joint infection (PJI) results in similar cure rate than two-stage (around 85-92%), but antibiotic therapy duration is not well established. Th...
Observational Study
Medecine et maladies infectieuses. 2020 Oct;50(7):567-574. DOI:10.1016/j.medmal.2020.03.003 2020
J P Stahl
J P Stahl
[Tracheal rhinoscleroma] [0.03%]
气管鼻纤毛囊肿病
N Romdhane,I Zoghlami,R Fradi et al.
N Romdhane et al.
RéJIF: The expanding network of French young infectious disease specialists [0.03%]
法国青年传染病专家的扩展网络： RéJIF
V Greigert,N Peiffer-Smadja,F Roblot et al.
V Greigert et al.
Interleukin-6 as a potential biomarker of COVID-19 progression [0.03%]
interleukin-6作为COVID-19进展的潜在生物标志物
Zulvikar Syambani Ulhaq,Gita Vita Soraya
Zulvikar Syambani Ulhaq
L Wang
L Wang
Background: COVID-19 is a new infectious disease, for which there is currently no treatment. It is therefore necessary to explore biomarkers to determine the extent of lung lesions and disease severity. ...
Severe extrarenal manifestations of nephropathia epidemica induced by Puumala hantavirus in two family cases [0.03%]
普马拉汉坦病毒引起的流行性肾病2个家庭病例的严重非肾脏表现
L Duez,T-A Ho,T Ledent et al.
L Duez et al.
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection [0.03%]
羟氯喹联合阿奇霉素治疗严重COVID-19患者没有快速的抗病毒作用或临床益处证据
J M Molina,C Delaugerre,J Le Goff et al.
J M Molina et al.